par Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R;Peto, C;Davies, J;Godwin, Richard;Gray, Huade;Pan, M;Clarke, D;Cutter, S;Darby, P;McGale, C;Taylor, Yue;Wang, Jonas;Bergh, Angelo;Di Leo, Kathy S
;Albain, S;Swain, Martine;Piccart-Gebhart, Kathleen
;Pritchard,
Référence Lancet, 379, 9814, page (432-444)
Publication Publié, 2012-02


Référence Lancet, 379, 9814, page (432-444)
Publication Publié, 2012-02
Article révisé par les pairs
Résumé : | Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices. We sought any such differences. |